ClinicalTrials.gg
Enrolling by invitationNCT07335432Vit C in TAHUpdated Jan 13, 2026

RCT - Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy

An interventional study of Vitamin C (Ascorbic Acid) in Myoma;Uterus and Adenomyosis of Uterus, sponsored by Queen Savang Vadhana Memorial Hospital, Thailand. Enrolling by invitation at 1 site in Thailand. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Queen Savang Vadhana Memorial Hospital, Thailand · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Sep 2024, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Study summary

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

The primary outcome was to compare intraoperative blood loss between patients who received intravenous Vitamin C and those who did not, following an abdominal hysterectomy under general anesthesia.

Intraoperative estimated blood loss (EBL) was meticulously quantified by weighing surgical gauze and measuring suction canister volumes.

The secondary outcomes were to evaluate the potential benefits of Vitamin C administration, including:

  • Reduction in the decline of hematocrit levels after surgery.
  • Reduction of the length of hospital stay
02

Conditions studied

  • Myoma;Uterus
  • Adenomyosis of Uterus

Keywords

  • Vitamin C
  • Total abdominal hysterectomy
  • Blood loss
03

In context

Adenomyosis

142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 78 interventional studies indexed under Adenomyosis.

Browse Adenomyosis studies →

Lead sponsor

Queen Savang Vadhana Memorial Hospital, Thailand is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients who underwent total abdominal hysterectomy

    • No bleeding tendency.
    • No history of anticoagulant or thrombolytic drug use
    • No to vitamin C supplementation

Exclusion criteria

Exclusion Criteria:

  • Inability to communicate in the Thai language.

    • Underwent total abdominal hysterectomy due to gynecologic .
    • Required emergency total abdominal hysterectomy.
    • History of vitamin C supplementation within 2 weeks prior to surgery.
    • History of smoking.
    • Previous abdominal surgery, such as bowel surgery, cesarean section
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental: Vitamin C

    Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

    Dietary Supplement: Vitamin C (Ascorbic Acid)

  • Experimental
    Placebo

    Dietary Supplement: Vitamin C (Ascorbic Acid)

Interventions

  • Dietary supplementAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision.

06

What researchers measure

Primary outcomes

  1. Intraoperative estimate blood loss

    Time frame: intraoperative

07

Study locations

1 site
  • Queen Savang Vadhana Memorial hospital
    Si Racha, Changwat Chon Buri 20110, Thailand
08

References and documents

Individual participant data

Plan to share: Undecided — Data was save in form of microsoft excel spreadsheet and SPSS file

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jul 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 13, 2026
StartActual
Sep 1, 2024
Primary completionActual
Jul 31, 2025
CompletionEst.
Jul 31, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335432
Lead sponsor
Queen Savang Vadhana Memorial Hospital, Thailand
Responsible party
Aektanat Tawornkitpanich (M.D., Queen Savang Vadhana Memorial Hospital, Thailand) — Principal investigator
First posted
Jan 13, 2026
Start date
Sep 1, 2024
Primary completion
Jul 31, 2025
Completion
Jul 31, 2026 (estimated)
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion